DiaSorin (OTCMKTS:DSRLF) Shares Gap Down – Should You Sell?

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $78.45, but opened at $74.25. DiaSorin shares last traded at $74.25, with a volume of 10 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. UBS Group downgraded DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Zacks Research raised DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Piper Sandler started coverage on DiaSorin in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft cut shares of DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, DiaSorin currently has an average rating of “Hold”.

DiaSorin Trading Down 11.7%

The company has a fifty day moving average price of $72.26 and a two-hundred day moving average price of $75.52.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.